Nanomedicine: Nanotechnology in Healthcare

Nanoparticle Drug Delivery

Conventional drugs: poor solubility, systemic toxicity, non-specific distribution. Nanoparticle carriers (10-200 nm): improved bioavailability, targeted delivery, controlled release. Liposomes: lipid bilayer vesicles (Doxil® — first FDA-approved nanodrug, 1995). Polymeric nanoparticles: PLGA, PLA, chitosan — biodegradable, tunable release. Lipid nanoparticles (LNPs): mRNA vaccine delivery (Pfizer/BioNTech, Moderna COVID-19 vaccines). EPR effect (Enhanced Permeability and Retention): tumor vasculature leakier than normal — passive targeting. Active targeting: surface ligands (antibodies, peptides, folate) bind specific cell receptors. Stimuli-responsive release: pH (tumor microenvironment pH 6.5-6.8), temperature, light, enzymes.

Nanodiagnostics

Gold nanoparticle-based lateral flow assays: pregnancy tests, COVID rapid tests — colorimetric detection. Quantum dots: semiconductor nanocrystals with tunable fluorescence, multiplexed biomarker detection. Magnetic nanoparticles: MRI contrast agents (superparamagnetic iron oxide — SPIO), magnetic separation of cells/biomarkers. Carbon nanotubes and graphene: electrochemical biosensors with femtomolar sensitivity. Surface Plasmon Resonance (SPR): gold nanofilm-based real-time binding kinetics. Nanocantilevers: mass-based detection of single molecules. Lab-on-a-chip: microfluidic devices integrating sample preparation, reaction, and detection. Point-of-care diagnostics: rapid, portable, low-cost testing in resource-limited settings.

Nano-imaging and Theranostics

Theranostics = therapy + diagnostics in one nanoplatform. Superparamagnetic nanoparticles: MRI imaging + hyperthermia treatment (alternating magnetic field heats tumor). Photoacoustic imaging: laser pulse → nanoparticle absorption → acoustic signal — combines optical contrast with ultrasound depth. Upconversion nanoparticles: near-infrared excitation → visible emission — deep tissue imaging with low autofluorescence. Gold nanorods: photothermal therapy (NIR laser heats tumor to 42-48°C). Radiolabeled nanoparticles: PET/SPECT imaging combined with targeted therapy. Multimodal imaging: single nanoparticle detectable by MRI + CT + fluorescence.

Nanorobotics

DNA nanorobots: barrel-shaped DNA origami structures that open in response to molecular signals, releasing payloads (Douglas et al., 2012). Molecular motors: kinesin-inspired walkers on DNA tracks. Sperm-driven microrobots: sperm cells loaded with drugs, guided by magnetic field to tumor. Magnetotactic bacteria: natural magnetic nanoparticle-containing bacteria steered by external fields (Martel lab). Synthetic microswimmers: catalytic Janus particles propelled by H₂O₂ decomposition. Challenges: in vivo navigation, immune evasion, real-time tracking, biocompatibility, regulatory pathways. Future: swarms of cooperating nanorobots for precision surgery and targeted drug delivery.

Clinical Translation Challenges

Only ~100 nanomedicines FDA-approved (vs. thousands in research). "Valley of death" between lab and clinic: manufacturing scalability, batch-to-batch reproducibility. Protein corona: plasma proteins adsorb on nanoparticle surface, changing targeting properties. Immunogenicity: anti-PEG antibodies after repeated LNP administration. Regulatory challenges: characterization requirements for complex nanomaterials. Cost: nanoformulations often more expensive than conventional drugs. Patient stratification: EPR effect varies significantly between patients and tumors. Accelerated by COVID-19: LNP technology validated at global scale, paving way for mRNA therapeutics in cancer, genetic diseases.

Try it live

Everything above runs in your browser — open Brownian Motion — Nanoparticle Diffusion Simulator and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.